Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| easypod connect: A regional, Multicentre, Observational study to evaluate Adherenceand Long Term Outcomes of Therapy in Paediatric subjects using “easypodTM” electromechanical device for growth hormone treatment | Merck Serono | Ongoing | N/A | 4 | EMR200104-534 | King Fahad University Hospital (Al-Khobar), alhabib |
| Observational Prospective STudy In Management of 1st line KRAS Wildtype mCRC with Erbitux™ (Cetuximab)- OPTIM1SE | Merck Serono | Ongoing | Erbitux (Cetuximab) | 4 | EMR062202-561 | King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), Prince Sultan Military Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial | King Abdullah Medical City, Makkah | Ongoing | DEXMEDETOMIDINE | 2 | 14-119 | King Abdullah Medical City (Makkah) |
| AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria in patients refractory to H1-antihistamine therapy | Novartis | Ongoing | N/A | 4 | E3401 | King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Non transfusion dependent Thalassemia Drug Registry | Novartis | Ongoing | Exjade (Deferasirox) | 4 | E2422 | King Abdulaziz University Hospital (Jeddah), King Abdulaziz Medical City NG (Jeddah), King Khalid University Hospital (Riyadh) |
| CogniPlus Study assessing Cognitive performance plus Physical activity in patients with Relapsing-Remitting MS under treatment with Betaferon® | Bayer | Ongoing | Betaferon | 4 | 16036 | King Fahad Hospital (Madinah), Security Forces Hospital (Riyadh), Aseer Central Hospital, King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), King Abdul Aziz Specialist hospital (Taif), King Fahad Specialist Hospital (Dammam) |
| International Registry to assess mEdical Practice withlOngitudinal obseRvation for Treatment of Heart Failure(REPORT-HF) | Novartis | Ongoing | N/A | 4 | 2401 | King Fahad Specialist Hospital (Dammam) |
| A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer | Novartis | Ongoing | LEE011 (Ribociclib) | 3 | CLEE011E2301 | King Khalid University Hospital (Riyadh)_ King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase IIIb, Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness & Safety of the use of Carbaglu® in Patients with Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA) | KAIMRC | Ongoing | Carglumic acid | 3 | IIT-OE-2013-001 | King Abdulaziz Medical City NG (Riyadh)_ King Fahad Medical City (Riyadh) |
| A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | Bayer | Ongoing | Sorafenib | 3 | BAY43-9006/14295 | King Faisal Specialist Hospital and Research Center (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.